SG10201404913QA - Inhibitors of cognitive decline - Google Patents
Inhibitors of cognitive declineInfo
- Publication number
- SG10201404913QA SG10201404913QA SG10201404913QA SG10201404913QA SG10201404913QA SG 10201404913Q A SG10201404913Q A SG 10201404913QA SG 10201404913Q A SG10201404913Q A SG 10201404913QA SG 10201404913Q A SG10201404913Q A SG 10201404913QA SG 10201404913Q A SG10201404913Q A SG 10201404913QA
- Authority
- SG
- Singapore
- Prior art keywords
- inhibitors
- cognitive decline
- cognitive
- decline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/02—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/10—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16798409P | 2009-04-09 | 2009-04-09 | |
| US30866710P | 2010-02-26 | 2010-02-26 | |
| US30909110P | 2010-03-01 | 2010-03-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201404913QA true SG10201404913QA (en) | 2014-11-27 |
Family
ID=42936539
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2011091352A SG176772A1 (en) | 2009-04-09 | 2010-04-06 | Inhibitors of cognitive decline |
| SG10201404913QA SG10201404913QA (en) | 2009-04-09 | 2010-04-06 | Inhibitors of cognitive decline |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2011091352A SG176772A1 (en) | 2009-04-09 | 2010-04-06 | Inhibitors of cognitive decline |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US8765816B2 (en) |
| EP (1) | EP2416795B1 (en) |
| JP (1) | JP2012523418A (en) |
| CN (2) | CN105968022A (en) |
| AU (2) | AU2010234518A1 (en) |
| BR (1) | BRPI1007624A2 (en) |
| DK (1) | DK2416795T3 (en) |
| ES (1) | ES2545795T3 (en) |
| HK (1) | HK1167323A1 (en) |
| IL (1) | IL215645A0 (en) |
| RU (1) | RU2595720C2 (en) |
| SG (2) | SG176772A1 (en) |
| WO (1) | WO2010118055A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG176772A1 (en) | 2009-04-09 | 2012-01-30 | Cognition Therapeutics Inc | Inhibitors of cognitive decline |
| ES2547730T3 (en) | 2009-07-31 | 2015-10-08 | Cognition Therapeutics, Inc. | Cognitive impairment inhibitors |
| AU2012212219B2 (en) | 2011-02-02 | 2017-03-23 | Cognition Therapeutics, Inc. | Isolated compounds from turmeric oil and methods of use |
| AU2012298614A1 (en) * | 2011-08-25 | 2014-04-10 | Cognition Therapeutics, Inc. | Compositions and methods for treating neurodegenerative disease |
| EP2747768A4 (en) * | 2011-08-25 | 2015-10-21 | Cognition Therapeutics Inc | Compositions and methods for treating neurodegenerative disease |
| JP2015512383A (en) | 2012-03-20 | 2015-04-27 | アダムド エスピー．ゼット オー．オー．Ａｄａｍｅｄ Ｓｐ．Ｚ Ｏ．Ｏ． | Sulfonamide derivatives of benzylamine for the treatment of CNS diseases |
| PL3062791T3 (en) * | 2013-10-28 | 2020-06-15 | Drexel University | Novel treatments for attention and cognitive disorders, and for dementia associated with a neurodegenerative disorder |
| AU2015210852B2 (en) | 2014-01-31 | 2019-01-24 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
| CA3061787A1 (en) | 2017-05-15 | 2018-11-22 | Cognition Therapeutics, Inc. | Compositions for treating neurodegenerative diseases |
| WO2021236879A1 (en) | 2020-05-20 | 2021-11-25 | The Board Of Trustees Of The University Of Illinois | Method for treating lysosomal storage diseases with histatin peptides |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4321386A (en) * | 1981-01-28 | 1982-03-23 | Mead Johnson & Company | Quaternary piperidinium halides |
| JPS62283922A (en) * | 1986-05-30 | 1987-12-09 | Tsumura Juntendo Inc | Platelet coagulation inhibiting agent |
| US4697024A (en) | 1986-11-24 | 1987-09-29 | Merrell Dow Pharmaceuticals Inc. | Medroxalol intermediates |
| JPH01180822A (en) * | 1988-01-12 | 1989-07-18 | Dainippon Pharmaceut Co Ltd | Anti-delayed type allergic agent |
| CA2071897A1 (en) | 1989-12-28 | 1991-06-29 | Richard A. Glennon | Sigma receptor ligands and the use thereof |
| DE4000610A1 (en) | 1990-01-11 | 1991-07-18 | Knoll Ag | Optically active 1-aryl-3-amino-butane derivs. prodn. - by fractional crystallisation of salts with optically active acid, useful as pharmaceutical intermediates |
| JP2818958B2 (en) * | 1990-02-23 | 1998-10-30 | 塩野義製薬株式会社 | 4- (4-Alkoxyphenyl) -2-butylamine derivative and method for producing the same |
| DE4142366A1 (en) | 1991-07-15 | 1993-06-24 | Thomae Gmbh Dr K | New phenylalkyl derivs. - are angiotensin II antagonists used to treat hypertension, coronary insufficiency, angina, cns disorders etc. |
| DK0724561T3 (en) * | 1991-08-23 | 2004-06-28 | Nps Pharma Inc | Calcium receptor active arylalkylamines |
| US6011068A (en) * | 1991-08-23 | 2000-01-04 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| CN1093079A (en) * | 1993-03-30 | 1994-10-05 | 陈英俊 | The adrenaline B-blocking agent of deriving by condiment compound with methyl catechol structure and dehydro-compound thereof |
| DK1203761T3 (en) * | 1994-12-08 | 2005-04-11 | Nps Pharma Inc | Calcium receptor active compounds |
| EP0881220A4 (en) | 1996-02-15 | 1999-04-21 | Mitsubishi Chem Corp | Diarylsultam derivatives |
| US6518315B1 (en) | 1997-10-21 | 2003-02-11 | The University Of Sydney | Medicinal uses of phenylaikanols and derivatives |
| MXPA02001095A (en) * | 1999-07-30 | 2002-08-20 | Vertex Pharma | Acyclic and cyclic amine derivatives. |
| WO2001030335A2 (en) | 1999-10-22 | 2001-05-03 | The Board Of Trustees Of The University Of Illinois | Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease |
| JP4312402B2 (en) | 2001-07-31 | 2009-08-12 | 有限会社大長企画 | Anti-depressant, anti-menopausal agent, anti-senile dementia agent, anti-Alzheimer agent |
| US20030073681A1 (en) * | 2001-08-21 | 2003-04-17 | Hauske James R. | 2-substituted piperidines that are ligands for monoamine receptors and transporters |
| US6991814B2 (en) | 2001-12-13 | 2006-01-31 | Council Of Scientific And Industrial Research | Herbal medicaments for the treatment of neurocerebrovascular disorders |
| JP2004002517A (en) * | 2002-05-31 | 2004-01-08 | Dae Sil Kim | Composition of soap containing ginger ingredient and method for producing the same |
| DE10320560A1 (en) | 2003-05-07 | 2004-01-29 | Brosig, Stefan, Dr. | Prophylaxis or treatment of Alzheimer's disease and/or Parkinson's disease, by administration of ginger, specifically in food and/or as ginger extract |
| WO2004110387A2 (en) | 2003-06-12 | 2004-12-23 | Agy Therapeutics, Inc. | Sigma ligands for neuronal regeneration and functional recovery |
| AU2005253776B8 (en) | 2004-06-21 | 2012-02-02 | King's College London | Screening methods using c-Abl, Fyn and Syk in combination with tau protein |
| TW200613272A (en) | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
| AU2005281783A1 (en) | 2004-09-10 | 2006-03-16 | Ucb Pharma, S.A. | Sigma receptor ligands |
| GB0423356D0 (en) * | 2004-10-21 | 2004-11-24 | Merck Sharp & Dohme | Therapeutic agents |
| EP1861422B1 (en) | 2005-03-05 | 2010-02-24 | Abbott GmbH & Co. KG | Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies |
| CA2611489A1 (en) | 2005-06-15 | 2006-12-28 | Darrick S.H.L. Kim | Synergistic pharmaceutical compositions useful in prevention and treatment of beta-amyloid protein-induced disease including sage and rosemary derived compounds |
| EP1745778A3 (en) | 2005-07-20 | 2007-03-07 | Speedel Experimenta AG | Diaminoalcohols as therapeutic compounds |
| ITRM20060007A1 (en) | 2006-01-05 | 2007-07-06 | Univ Bari | SIGMA-2 RECEPTOR METHOD OF SCREENING OF SPECIFIC LIGANDS AND USE OF THE SAME IN DIAGNOSTIC OR THERAPEUTIC METHODS |
| US20080193573A1 (en) | 2006-03-17 | 2008-08-14 | Gow Robert T | Extracts and methods comprising curcuma species |
| US20100029654A1 (en) | 2006-03-23 | 2010-02-04 | Mount Sinai School Of Medicine | Cardiovascular compositions and use of the same for the treatment of alzheimer's disease |
| US7561775B2 (en) | 2006-08-22 | 2009-07-14 | Senko Advanced Components, Inc. | Fiber optic protective shutter |
| US7723377B2 (en) | 2006-09-29 | 2010-05-25 | Cognition Therapeutics, Inc. | Inhibitors of cognitive decline |
| WO2008076262A2 (en) | 2006-12-15 | 2008-06-26 | Merck & Co., Inc. | Receptor for amyloid beta and uses thereof |
| CN101808647A (en) | 2007-05-15 | 2010-08-18 | 海利空医疗公司 | Methods of treating cognitive disorders by inhibition of Gpr12 |
| WO2009054468A1 (en) * | 2007-10-24 | 2009-04-30 | Astellas Pharma Inc. | Azolecarboxamide compound or salt thereof |
| WO2009059214A1 (en) | 2007-11-02 | 2009-05-07 | The Regents Of The University Of California | Abeta-binding small molecules |
| WO2010062260A1 (en) | 2008-11-29 | 2010-06-03 | The Thailand Research Fund | Virus and target cell interaction inhibition |
| SG176772A1 (en) | 2009-04-09 | 2012-01-30 | Cognition Therapeutics Inc | Inhibitors of cognitive decline |
| ES2547730T3 (en) | 2009-07-31 | 2015-10-08 | Cognition Therapeutics, Inc. | Cognitive impairment inhibitors |
| US20130071330A1 (en) | 2010-02-26 | 2013-03-21 | Susan Catalano | Methods of identifying agents effective to treat cognitive decline and diseases associated therewith |
| AU2012298614A1 (en) | 2011-08-25 | 2014-04-10 | Cognition Therapeutics, Inc. | Compositions and methods for treating neurodegenerative disease |
-
2010
- 2010-04-06 SG SG2011091352A patent/SG176772A1/en unknown
- 2010-04-06 CN CN201610113476.5A patent/CN105968022A/en active Pending
- 2010-04-06 WO PCT/US2010/030130 patent/WO2010118055A1/en active Application Filing
- 2010-04-06 RU RU2011145321/04A patent/RU2595720C2/en not_active Application Discontinuation
- 2010-04-06 US US13/263,162 patent/US8765816B2/en active Active
- 2010-04-06 CN CN2010800257716A patent/CN102458435A/en active Pending
- 2010-04-06 DK DK10762322.5T patent/DK2416795T3/en active
- 2010-04-06 JP JP2012504788A patent/JP2012523418A/en active Pending
- 2010-04-06 AU AU2010234518A patent/AU2010234518A1/en not_active Abandoned
- 2010-04-06 ES ES10762322.5T patent/ES2545795T3/en active Active
- 2010-04-06 BR BRPI1007624A patent/BRPI1007624A2/en not_active Application Discontinuation
- 2010-04-06 SG SG10201404913QA patent/SG10201404913QA/en unknown
- 2010-04-06 EP EP10762322.5A patent/EP2416795B1/en active Active
-
2011
- 2011-10-09 IL IL215645A patent/IL215645A0/en unknown
-
2012
- 2012-08-15 HK HK12108018.7A patent/HK1167323A1/en not_active IP Right Cessation
-
2014
- 2014-06-02 US US14/293,755 patent/US9365491B2/en active Active
-
2015
- 2015-10-12 AU AU2015242954A patent/AU2015242954B2/en not_active Ceased
-
2016
- 2016-06-13 US US15/181,211 patent/US20160355458A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DK2416795T3 (en) | 2015-08-31 |
| HK1167323A1 (en) | 2013-01-04 |
| JP2012523418A (en) | 2012-10-04 |
| EP2416795A1 (en) | 2012-02-15 |
| AU2010234518A1 (en) | 2012-02-02 |
| RU2011145321A (en) | 2013-05-20 |
| US9365491B2 (en) | 2016-06-14 |
| RU2595720C2 (en) | 2016-08-27 |
| CN105968022A (en) | 2016-09-28 |
| SG176772A1 (en) | 2012-01-30 |
| EP2416795A4 (en) | 2013-12-25 |
| US20120095105A1 (en) | 2012-04-19 |
| US8765816B2 (en) | 2014-07-01 |
| AU2015242954A1 (en) | 2015-10-29 |
| US20140371324A1 (en) | 2014-12-18 |
| AU2015242954B2 (en) | 2016-08-25 |
| EP2416795B1 (en) | 2015-06-03 |
| US20160355458A1 (en) | 2016-12-08 |
| BRPI1007624A2 (en) | 2016-07-26 |
| CN102458435A (en) | 2012-05-16 |
| WO2010118055A1 (en) | 2010-10-14 |
| ES2545795T3 (en) | 2015-09-15 |
| IL215645A0 (en) | 2012-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201700326B (en) | Inhibitors of beta-secretase | |
| EP2391623A4 (en) | Inhibitors of akt activity | |
| EP2440054A4 (en) | Pyridil-triazine inhibitors of hedgehog signaling | |
| ZA201206424B (en) | Inhibitors of semicarabazide-sensitive amine oxidase | |
| EP2413932A4 (en) | Inhibitors of akt activity | |
| PL2521746T3 (en) | Inhibition of amine oxidation | |
| IL218018A0 (en) | Novel n-substituted-pyrrolidines as inhibitors of mdm2-p-53 interactions | |
| EP2406250A4 (en) | Inhibitors of akt activity | |
| HK1171624A1 (en) | Inhibitors of cognitive decline | |
| HK1167323A1 (en) | Inhibitors of cognitive decline | |
| ZA201206456B (en) | Uses of dgati inhibitors | |
| EP2405756A4 (en) | Inhibitors of akt activity | |
| SI2506840T1 (en) | Uses of hypoxia-inducible factor inhibitors | |
| HK1167654A1 (en) | Dihydropyrrolonaphtyridinone compounds as inhibitors of jak jak dihydropyrrolonaphtyridinone | |
| HK1171013A1 (en) | Inhibitors of akt activity akt | |
| PL2493496T3 (en) | Use of gstp1 | |
| IL217756A0 (en) | Inhibitors of jnk | |
| GB0908609D0 (en) | New use of isoQC inhibitors | |
| LU91725B1 (en) | Novel uses of V-ATPASE inhibitors | |
| EP2513059A4 (en) | Inhibitors of akt activity | |
| GB0903651D0 (en) | Inhibitors of glyoxalase | |
| GB0905098D0 (en) | Use of biomarkers | |
| GB0905280D0 (en) | Novel uses of VEGFxxxb | |
| IL220242A0 (en) | Methods of improving cognitive functions | |
| GB0911084D0 (en) | New use of statins |